新股消息 | 先通医药递表港交所 为中国首家获得创新放射性药物上市批准的企业

Core Viewpoint - Xiantong Pharmaceutical is the first company in China to receive approval for innovative radiopharmaceuticals, focusing on the development and commercialization of leading-edge products in the radiopharmaceutical market [1][4]. Company Overview - Xiantong Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CICC and CITIC Securities as joint sponsors [1]. - The company is a leader in the Chinese radiopharmaceutical market, aiming to develop and commercialize innovative products with the potential to be the first of their kind or best in class [4]. Product Pipeline - The company's pipeline focuses on oncology, neurodegenerative diseases, and cardiovascular diseases, comprising 15 assets, including four core products: XTR008, XTR006, XTR004, and XTR003 [4]. - XTR008 is a registered Lu-labeled somatostatin receptor-targeted radioligand for treating neuroendocrine tumors [4]. - XTR006 is a potential best-in-class F-labeled tau-targeted PET diagnostic radioligand for diagnosing suspected Alzheimer's disease or mild cognitive impairment due to Alzheimer's [4]. - XTR004 is an F-labeled mitochondrial complex I-targeted diagnostic radioligand for PET myocardial perfusion imaging [5]. - XTR003 is a potential first-in-class F-labeled PET diagnostic radioligand for myocardial fatty acid metabolism imaging [5]. Commercialization and Production - Three assets are in commercialization or near commercialization, eight are in clinical or IND supportive stages, and four are in investigator-initiated trials or preclinical research [4]. - The company has established two production bases in Wuxi, Jiangsu, and Zhongshan, Guangdong, with a total building area exceeding 20,000 square meters and 12 commercial-scale production lines [5]. - A third production base in Mianyang, Sichuan, is expected to commence operations in Q3 2025 [5]. Financial Performance - For the fiscal years 2023 and 2024, Xiantong Pharmaceutical reported revenues of approximately RMB 10.232 million and RMB 44.064 million, respectively, with net losses of approximately RMB 309.234 million and RMB 156.116 million [6][7]. - The company experienced a significant increase in revenue from 2023 to 2024, while also reducing its net loss [6][7].